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Background: The childhood neuromuscular disease spinal muscular atrophy (SMA) is caused by mutations or
deletions of the survival motor neuron (SMN1) gene. Although SMA has traditionally been considered a motor
neuron disease, the muscle-specific requirement for SMN has never been fully defined. Therefore, the purpose of
this study was to investigate muscle defects in mouse models of SMA.
Methods: We have taken advantage of two different mouse models of SMA, the severe Smn−/−;SMN2 mice and the
less severe Smn2B/− mice. We have measured the maximal force produced from control muscles and those of SMA
model mice by direct stimulation using an ex vivo apparatus. Immunofluorescence and immunoblot experiments
were performed to uncover muscle defects in mouse models of SMA. Means from control and SMA model mice
samples were compared using an analysis of variance test and Student’s t tests.
Results: We report that tibialis anterior (TA) muscles of phenotype stage Smn−/−;SMN2 mice generate 39% less
maximal force than muscles from control mice, independently of aberrant motor neuron signal transmission. In
addition, during muscle fatigue, the Smn−/−;SMN2 muscle shows early onset and increased unstimulated force
compared with controls. Moreover, we demonstrate a significant decrease in force production in muscles from pre-
symptomatic Smn−/−;SMN2 and Smn2B/− mice, indicating that muscle weakness is an early event occurring prior to
any overt motor neuron loss and muscle denervation. Muscle weakness in mouse models of SMA was associated
with a delay in the transition from neonatal to adult isoforms of proteins important for proper muscle contractions,
such as ryanodine receptors and sodium channels. Immunoblot analyses of extracts from hindlimb skeletal muscle
revealed aberrant levels of the sarcoplasmic reticulum Ca2+ ATPase.
Conclusions: The findings from this study reveal a delay in the appearance of mature isoforms of proteins
important for muscle contractions, as well as muscle weakness early in the disease etiology, thus highlighting the
contributions of skeletal muscle defects to the SMA phenotype.
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With an overall carrier frequency of 1:40, spinal muscu-
lar atrophy (SMA) is a major leading genetic cause of
infant deaths, affecting 1 in 6,000 to 10,000 births [1-3].
Spinal muscular atrophy is an autosomal recessive dis-
order traditionally classified into different types based on
the clinical severity of the symptoms [4]. In 1995, the
SMA-determining gene was identified and named
‘survival motor neuron’ (SMN) [5]. This gene is located
on chromosome 5q13 in humans, in a region containing
an inverted duplication of 500 kilobase pairs. This
results in two virtually identical copies of the SMN gene;
SMN1 and SMN2 [5-8].
In the mouse, the Smn gene is present as a single copy,
and homozygous loss of function leads to a pre-
implantation lethality [9]. However, when the Smn knock-
out is coupled with low levels of human SMN expressed
from a SMN2 transgene, a severe phenotype approximat-
ing type I SMA is observed in Smn−/−;SMN2 mice [10].
Since this original discovery, several other mouse models
of SMA have been generated, including a milder model
termed Smn2B/−. These latter mice do not harbor the
SMN2 transgene but rather harbor one null allele and a
second allele with a 3-nucleotide substitution in the
exonic splice enhancer of exon 7 of the mouse Smn gene
(2B mutation) [11]. Smn2B/- model mice display a milder
SMA phenotype, owing to slightly higher Smn protein
levels than the severe model [12].
Motor neuron cell loss and muscle denervation are
considered two pathological hallmarks of SMA. Exactly
how SMN depletion leads to motor neuron degeneration
is unclear and remains the focus of intense research. In
addition, recent advances in the field have highlighted
the involvement of other tissues in the pathophysiology
of SMA, of which skeletal muscle appears to be an
important candidate [4,13].
In Drosophila, Smn was discovered to be a sarcomeric
protein interacting with α-actinin, a cross-linking pro-
tein that stabilizes actin microfilaments [14]. Walker and
colleagues later confirmed these findings and specifically
identified Smn as a Z-disc component in skeletal and
cardiac muscle of mice [15]. At present, the function of
Smn at this adhesion site is unknown but Smn is likely
to have a specific function other than snRNP biogenesis
in muscle [15]. An Smn interacting protein screen in
C2C12 myoblasts suggests that the function of Smn in
muscle is dynamic and probably differs during varying
stages of myogenesis based on its protein interactome
[16]. A proteomic screen performed by Mutsaers et al.
identified an increase in proteins involved in pro-
grammed cell death in pre-symptomatic Smn−/−;SMN2
mice [17]. Several reports have highlighted the possibil-
ity of delayed myogenesis in mouse models of SMA. The
basis of this notion comes from muscle morphologicalstudies demonstrating a lack of increase in myofiber size
and the increased levels of embryonic and neonatal
myosin heavy chain (MHC) isoforms [18-20]. However,
it is not known whether or how impaired muscle growth
contributes to muscle weakness in SMA, since at present
no comprehensive analysis has been performed relating
to muscle force production in mouse models of SMA.
Here, we show previously unreported pathophysio-
logical muscle defects in severe (Smn−/−;SMN2) and less
severe (Smn2B/−) mouse models of SMA. We report pro-
nounced muscle weakness in these mice. These observa-
tions were associated with altered expression of proteins
that are developmentally regulated and are important for
proper physiological muscle function. Furthermore, we
show that muscle weakness is an early feature, observed
prior to any overt motor neuron loss and muscle de-
nervation in mouse models of SMA. Thus, we conclude
that muscle defects contribute to the phenotype in SMA
mouse models. Uncovering skeletal muscle defects in
the context of SMA is of the utmost importance to bet-
ter understand the SMA phenotype and for the develop-
ment of targeted therapeutics.
Methods
Mouse models
The Smn−/−;SMN2 (Jackson Labs, Bar Harbor, ME, USA)
and Smn2B/− [12] mice were housed and cared for
according to the Canadian Council on Animal Care guide-
lines and the University of Ottawa Animal Care Commit-
tee protocols. Tissues from pre-symptomatic mice were
collected at postnatal day (P) 2 for severe Smn−/−;SMN2
mice, and P9 for Smn2B/− mice. Tissues were also col-
lected from phenotype stages at P5 for Smn−/−;SMN2
and P21 for Smn2B/− mice. Muscles used for RNA and
protein analysis were flash frozen in liquid nitrogen and
stored at −80°C.
Hindlimb denervation
Denervation surgeries were performed in accordance with
the guidelines set by the Canadian Council on Animal
Care. Young mice (P14) were anaesthetized by inhalation
of isoflurane. Experimental denervation was achieved by
revealing the sciatic nerve and removing 2 to 3 mm of the
nerve in the thigh section to cease neural input and pre-
vent nerve regrowth. A sham procedure was performed in
parallel to serve as control; this consisted of exposing the
mice to identical experimental conditions except for cut-
ting the nerve. The TA muscles were collected and flash
frozen from denervated and sham operated mice one and
seven days following surgery.
Immunoblotting
Total tissue lysate extract was obtained by grinding flash
frozen tissues in a liquid nitrogen pre-cooled mortar and
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mined by Bradford assay. Samples were subjected to
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis and examined by immunoblot, as previously de-
scribed [16]. Primary antibodies used were: calsequestrin
(Abcam, Toronto, ON, Canada), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, Abcam, Toronto, ON,
Canada), Nav1.4 (Alomone, Jerusalem, Israel), Nav1.5
(Alomone, Jerusalem, Israel), nuclear factor 1 (Abcam,
Toronto, ON, Canada), sarcoplasmic reticulum Ca2+
ATPase (SERCA1a, Cell Signaling, Danvers, MA, USA),
and zinc-finger E box-binding protein (ZEB) (Novus Bio-
logicals, Littleton, CO, USA). Signals were detected using
enhanced chemiluminescence (Thermo, Florence, KY,
USA). Densitometric analyses were performed using ImageJ
software (NIH). Immunoblot data were normalized to
GAPDH levels to control for possible loading differences.
Force measurements and fatigue protocol
The TA muscles were dissected from P2 and P5 control
and severe Smn−/−;SMN2 mice, and from P9 control and
Smn2B/− mice. Muscles were constantly immersed in
physiological saline solution containing 118.5 mM NaCl,
4.7 mM KCl, 2.4 mM CaCl2, 3.1 mM MgCl2, 25 mM
NaHCO3, 2 mM NaH2PO4, and 5.5 mM D-glucose. Solu-
tions were continuously bubbled with 95% O2, 5% CO2 for
a pH of 7.4. Solutions containing 30 μM of tubocurarine
hydrochloride pentahydrate (Sigma, Oakville, ON, Canada)
were prepared by adding the appropriate amount directly
to the physiological solution. The flow of physiological so-
lution below and above muscles was maintained at a total
of 15 ml/min and a temperature of 37°C. Tetanic contrac-
tions were elicited with electrical stimulations applied
across two platinum wires (4 mm apart) located on oppos-
ite sides of the muscle. Electrodes were connected to a
Grass S88 stimulator and a Grass SIU5 isolation unit
(Grass Technologies/Astro-Med Inc., Warwick, RI, USA).
Tetanic contractions were elicited with 200 ms trains of
0.3 ms, 12 V (supramaximal voltage) pulses at a frequency
of 200 Hz. For all experiments, muscle length was adjusted
to achieve maximal force production and muscles were
allowed a 30 min equilibration period during which a tet-
anic contraction was elicited every second. Maximal force
production was determined by increasing frequencies from
1 to 200 Hz. Muscles were then fatigued by increasing the
contraction rate to one contraction per second for 180 s.
Twitch (obtained when stimulated with one square pulse)
or tetanic force was defined as the force that developed
during stimulation and was calculated as the difference be-
tween the maximum force during contraction and the
force measured 5 ms before the contraction. Unstimulated
force was defined as the force generated by muscles in the
absence of electrical stimulation and was observed during
fatigue when muscles failed to relax between contractions;it was calculated as the difference in the baseline 5 ms be-
fore a contraction and the baseline 5 ms before fatigue was
elicited. Muscle weight and length were used to calculate
the cross-sectional area of the muscle that was used to
normalize force measurements in each experiment.
RNA isolation
Total RNA was isolated from skeletal muscle tissue using
a homogenizer and the RNeasy kit (Qiagen, Toronto, ON,
Canada) according to the manufacturer’s instructions.
RNA samples were treated with DNase (gDNA wipeout
buffer, Qiagen, Toronto, ON, Canada) to eliminate DNA
contamination and concentrations were determined using
a Nanophotometer spectrophotometer (MBI Lab Equip-
ment, Dorval, QC, Canada).
Reverse-transcription polymerase chain reaction (RT-PCR)
RNA was reverse-transcribed using the quantitect reverse-
transcription kit (Qiagen, Toronto, ON, Canada). Primer
sequences and PCR conditions used to detect the spliced
variants of the ryanodine receptor RyR1 gene were identi-
cal to those previously described [21]. A negative control
in which water was added instead of cDNA was prepared
in parallel for every PCR. Quantification of the RT-PCR
results was achieved using ImageJ software.
Immunofluorescence
Neuromuscular junction (NMJ) immunofluorescence and
quantification was performed as described previously [22].
Post-synaptic acetylcholine receptors were labeled with
α-bungarotoxin (Molecular Probes, Burlington, ON,
Canada) while the pre-synaptic terminal was labeled with
anti-neurofilament and anti-synaptic vesicle protein 2
(both from Developmental Studies Hybridoma Bank, Iowa
City, IA, USA). All secondary antibodies were purchased
from Jackson Labs. Immunofluorescence images were cap-
tured using a Zeiss Confocal microscope (LSM 510
Meta DuoScan, Toronto, ON, Canada). For each
muscle, four to six fields of view were quantified and a
total of counted endplates ranging between 99 and 263
were included per animal in the analysis.
Histological analysis
The lumbar (L1 and L2) region of the spinal cord was
collected from control, pre-symptomatic Smn−/−;SMN2
and Smn2B/− mice. Tissues were fixed in 4% paraformal-
dehyde for 24 hrs, embedded in paraffin, cut into sec-
tions (10 μm) and stained with hematoxylin and eosin
(H & E). Motor neurons were identified by their shape
and size within the ventral horn region of the spinal
cord. Motor neuron quantification was performed on
every fifth section within the L1 and L2 region on three
mice from each genotype. Histological analyses were also
performed on cross-sections (10 μm) from frozen TA
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tions were stained with H & E using a standard protocol,
images were taken with a Zeiss Axioplan2 microscope,
and the myofiber area was calculated using ImageJ soft-
ware. Approximately one thousand fibers were counted
for each genotype analyzed.Statistical analyses
Data are presented as the mean ± standard error of the
mean. Analysis of variance (Statistical Analysis Software
Institute Inc., Cary, NC, USA) was used to determine
significance in the fatigue data. A Student’s t test was
performed using MS Excel to compare the means of all
other data. Significance was set at P < 0.05.Results
Skeletal muscle weakness in Smn−/−;SMN2 mice
To date, no physiological study has been performed on
muscles from severe SMA model mice. To this end, we
have analyzed the twitch and peak tetanic force pro-
duced by direct stimulation of TA muscles of Smn−/−;
SMN2 mice and control littermates at P5. To account
for variations in muscle size, all force values were nor-
malized to muscle cross-sectional area. Compared with
control muscles, Smn−/−;SMN2 mice produced 47% less
twitch force, as measured after one stimulation, and 39%Figure 1 Muscle weakness in muscle from Smn−/−;SMN2 mice. (A) TA m
were used to assess tetanic and twitch force normalized to the muscle cro
twitch force than control littermates. (B) Reduction in normalized maximal
controls. (C) Administration of tubocurarine to block NMJs did not influenc
independent experiments, Smn−/−;SMN2 mice produced less force than con
decreases in Smn−/−;SMN2 and control mice during fatigue elicited with on
expressed as a percentage of the pre-fatigue force. (E) Unstimulated force
expressed as a percentage of the pre-fatigue peak tetanic force. During a f
unstimulated force compared with controls. (F) Unstimulated force appear
neuromuscular junction; TA, tibialis anterior; N = 5 or 6; *, P < 0.05.less maximum peak tetanic force, as measured at 200 Hz
(Figure 1A,B).
Aberrant NMJ morphology and function have previ-
ously been highlighted in several mouse models of SMA
[20,22-24]. In isolated muscle preparations, many fibers
receive an indirect stimulation via the remaining nerve
stump. Although it has previously been demonstrated
that the TA muscle is fully innervated in SMA model
mice [20,25], one possible explanation for the observed
decrease in force is that the applied stimulus enters the
residual nerve before reaching the myofibers. Thus, if
poorly functioning NMJs were present in the prepar-
ation, it would negatively impact the force because fewer
fibers would be stimulated. To address this possibility,
we measured the maximal force production in muscles
from control and mutant mice in the presence or ab-
sence of tubocurarine, which blocks acetylcholine recep-
tors. Should aberrant NMJs negatively affect TA muscle
force production, it would be expected that the relative
force produced by muscles from Smn−/−;SMN2 mice
would be equal to the control values in the presence of
tubocurarine. The force production of control muscles
was not affected by the presence of tubocurarine nor did
we observe an increase in force production in Smn−/−;
SMN2 muscles after the addition of tubocurarine to the
preparation compared with non-treated muscles (data not
shown). Furthermore, in five independent experiments,uscle preparations from P5 Smn−/−;SMN2 mice and control littermates
ss-sectional area. P5 Smn−/−;SMN2 TA muscles produce significantly less
peak tetanic force in P5 Smn−/−;SMN2 TA muscle compared with
e relative force production in Smn−/−;SMN2 muscles. In five
trols following treatment with tubocurarine. (D) Similar relative force
e tetanic contraction every second for 3 min. Peak tetanic forces are
occurred when muscles failed to relax between contractions and is
atigue protocol, P5 Smn−/−;SMN2 TA muscles show increased
ed much sooner in Smn−/−;SMN2 TA muscles than in controls. NMJ,
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lower than that of controls (Figure 1C). These data show
that at the phenotype stage, aberrant NMJs did not im-
pact Smn−/−;SMN2 TA ex vivo muscle force production
and that mechanisms of stimulus propagation might be
compromised in muscles from Smn−/−;SMN2 mice.
Smn−/−;SMN2 muscles respond abnormally to induced
muscle fatigue
To determine whether Smn−/−;SMN2 muscles respond
differently to muscle fatigue, we measured the decline in
force with repeated tetanic stimulation for 180 s. The
decrease in peak tetanic force recorded in Smn−/−;SMN2
muscles was similar to control littermates (Figure 1D).
During the fatigue protocol, we also measured the un-
stimulated force, which is defined as the force measured
100 ms before a contraction is elicited. The TA muscles
of both control and Smn−/−;SMN2 P5 mice generated an
increase in unstimulated force as they failed to com-
pletely relax between contractions (Figure 1E). However,
the Smn−/−;SMN2 muscle produced significantly more
unstimulated force than control counterparts. The un-
stimulated force of control TA muscles had a mean time
of appearance at 133 s and was equivalent to 4.4% of the
pre-fatigue tetanic force by the end of the protocol
(Figure 1E,F). However, for the P5 Smn−/−;SMN2 TA
muscles, the average time of appearance started signifi-
cantly sooner, i.e. at 49 s, with a final mean of 8.2%
(Figure 1E,F). Therefore, our results suggest the pres-
ence of a defect in Smn−/−;SMN2 muscles, resulting in
an inability to recover from muscle fatigue over time.
Pre-symptomatic muscle weakness in Smn−/−;SMN2 and
Smn2B/− mice
Whilst we observed a significant decrease in force pro-
duction in muscles from phenotypic Smn−/−;SMN2 mice,
which was independent of aberrant nerve transmission
in the ex vivo preparations, it remains possible that the
muscle weakness observed could be attributed to motor
neuron degeneration occurring prior to the stage of our
analyses. We therefore assessed the peak tetanic force in
pre-symptomatic mice. For this, we have extended our
analysis to include both Smn−/−;SMN2 and Smn2B/−
mouse models. This analysis was performed at pre-
phenotypic time point of P2 and P9 in Smn−/−;SMN2
and Smn2B/− model mice, respectively. To confirm that
these time points preceded neurodegenerative events,
we assessed motor neuron number and NMJ integrity.
At P2 in Smn−/−;SMN2 mice, and P9 in Smn2B/− mice,
there was no difference in the number of motor neuron
cell bodies compared with controls (Figure 2A,D). Fur-
thermore, the percentage of fully occupied endplates was
unchanged between each mouse model of SMA and the
respective controls (Figure 2E,H).Although we observed no overt motor neuron loss or
denervation in both models at pre-symptomatic stage, we
observed a significant decrease in peak tetanic force. TA
muscles from P2 Smn−/−;SMN2 mice produced 67% lower
peak tetanic force than control littermates (Figure 3A). TA
muscles from P9 Smn2B/− mice produced 61% lower peak
tetanic force than control littermates (Figure 3C). The
peak forces were normalized to the cross-sectional area of
each muscle; however, at this stage, we did not observe
any significant difference in mean fiber area between
mutant and control muscle in either Smn2B/− or Smn−/−;
SMN2 mice (Figure 3B,D). Taken together, these data
demonstrate that in two different mouse models of SMA,
muscle weakness is an early feature, occurring prior to
any overt motor neuron loss and denervation.
Decreased expression of mature ryanodine receptor 1
transcripts in muscle from SMA model mice
The results of our physiology experiments led us to in-
vestigate possible causes for the decrease in force pro-
duction from Smn−/−;SMN2 muscle. During a muscle
contraction, calcium is released from the sarcoplasmic
reticulum to the sarcomere to allow for the actin-myosin
cross-bridge cycling. The calcium release is mediated by
ryanodine receptor 1 (RyR1), which is the predominant
ryanodine receptor expressed in mature muscle [26].
Several splice variants of the RyR1 gene exist. For ex-
ample, one variant is called ASI and is expressed without
exon 70 [ASI (−)] in neonatal muscle and transitions to
an alternatively spliced variant that includes exon 70 in
mature skeletal muscle [ASI (+)] [27]. The second RyR1
splice variant is ASII, which is further spliced to exclude
exon 83 in immature muscle [ASII (−)] or to include
that exon in mature muscle [ASII (+)] [21,27]. Using
PCR primers designed to target the mature and imma-
ture variants, we assessed the RyR1 transcripts in hind-
limb skeletal muscle RNA extracts from mouse models
of SMA and in controls. A time course analysis demon-
strates the predominant expression of ASII (+) in mature
muscle (P21) over the ASII (−) variant in wild type mice
(Figure 4A). At P5, the predominant ASII isoform in
control mice was ASII (+), while in Smn−/−;SMN2 muscle
there was a relative increase in the proportion of the neo-
natal variant ASII (−) over ASII (+) (Figure 4B middle
panel and Figure 4D). In control P21 mice, the adult ASII
(+) variant was predominant relative to the neonatal ASII
(−) variant, whereas in Smn2B/− mice both variants were
expressed at similar levels (Figure 4C middle panel and
Figure 4D).
Using the same approach, we assessed the transcript
levels of ASI using primers targeting both the neonatal
and adult ASI splice variant. We did not observe any dif-
ference in neonatal versus adult transcript levels of the
ASI variant for the Smn−/−;SMN2 mice (Figure 4B upper
Figure 2 (See legend on next page.)
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Figure 2 Normal motor neuron counts and NMJ integrity in P2 Smn−/−;SMN2 and P9 Smn2B/− mice. (A, B) Representative images of H & E
staining of motor neurons in the ventral horn region of the L1 and L2 spinal cord region of P2 control and Smn−/−;SMN2 mice, and P9 control
and Smn2B/− mice. Scale bar = 50 μm. (C, D) Quantification of motor neuron cell body number within the ventral horn of the lumbar (L1 and L2)
region of the spinal cord for control and pre-symptomatic Smn−/−;SMN2 and Smn2B/− mice. (E, F) Representative images showing fully intact
NMJs from TA muscles of control and pre-symptomatic Smn−/−;SMN2 (E) and Smn2B/− (F) mice. Post-synaptic acetylcholine receptors were
labeled with α-bungarotoxin (red) while the pre-synaptic terminal was labeled with anti-NF (green) and anti-SV2 (green). Scale bar = 20 μm.
(G, H) Quantification of the percentage of fully occupied endplates revealed no difference between control and pre-symptomatic Smn−/−;SMN2
and Smn2B/− mice. NF, neurofilament; NMJ, neuromuscular junction; SV2, synaptic vesicle protein 2; N = 3 for all experiments.
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neonatal ASI (−) transcript was the predominant variant
expressed, while in control muscles, the ASI (+) transcript
was the major ASI variant expressed (Figure 4C upper
panel and Figure 4D). Collectively, the aberrant expression
pattern of the RyR1 transcripts suggests a delay in muscle
development in mouse models of SMA.
Muscle denervation at the NMJ is a pathological fea-
ture observed in mouse models of SMA. Although there
are generally low levels of denervation in the hindlimb
muscles of SMA model mice [28], we investigated whether
denervation would influence the expression the RyR1
transcript. To do so, we experimentally denervated mus-
cles of 2-week-old wild type mice and examined the ex-
pression of RyR1 in denervated samples compared with
sham controls. We did not detect any changes in theFigure 3 Pre-symptomatic muscle weakness in Smn−/−;SMN2 and Smn
decrease in maximal tetanic force production compared with controls. Forc
average peak tetanic force was reduced by 61% in P9 pre-symptomatic Sm
area of P2 TA muscles from Smn−/−;SMN2 and control mice. (D) Average fib
all experiments. *, P < 0.05.splicing pattern of the RyR1 ASII variants in denervation
compared with control samples, either one day or seven
days post-denervation (Figure 4E,F). These results support
the hypothesis that the changes in RyR1 splicing pattern
in muscles from the mouse models of SMA are not attrib-
utable to pre-synaptic pathology and are therefore poten-
tially reflective of a muscle developmental defect.
Altered sodium channel levels in SMA mice
In excitable cell types, such as neurons and myocytes,
sodium channels propagate the action potential. Sodium
channel expression is a developmentally regulated process
in which an isoform switch, Nav1.5 to Nav1.4, occurs dur-
ing postnatal development in the mouse [29,30]. Nav1.4,
the predominant sodium channel isoform in adult skeletal
muscle [31], must be expressed at the correct time point2B/− mice. (A) P2 Smn−/−;SMN2 force measurements revealed a 67%
e data were normalized to the muscle cross-sectional area. (B) The
n2B/− TA muscles compared with control littermates. (C) Mean fiber
er cross-sectional area for P9 Smn2B/− and control TA muscle. N = 3 for
Figure 4 Delayed expression of adult RyR1 mRNA splice variant in muscles from mouse models of SMA. (A) RT-PCR on RNA from
hindlimb muscle from wild type mice with primers directed against ASII (+) and ASII (−). GAPDH served as a loading control to confirm
equivalence of starting cDNA levels . Note that relative ratio of ASII (+) to ASII (−) increases from P2 to P21. (B) RT-PCR results demonstrated no
change in the expression of ASI (+) and ASI (−) variants in control and Smn−/−;SMN2 samples at P5 (upper panel). However, there was decreased
expression of ASII (+) and sustained expression of ASII (−) in muscle samples from P5 Smn−/−;SMN2 compared with controls (middle panel).
GAPDH served as a loading control. N = 5 for each genotype. (C) In control P21 mice, we observed increased expression of ASI (+) transcripts
relative to ASI (−) transcripts. However in Smn2B/− mice, the relative ratio of ASI (+) to ASI (−) transcripts was decreased (upper panel).
Furthermore, for the ASII variant, we observed the presence of a single transcript [ASII (+)] in P21 control samples, while in Smn2B/− samples, we
observed a decrease in ASII (+) transcripts compared with controls. The ASII (−) variant was also now apparent (middle panel). GAPDH served as a
loading control. N = 5 for each variant. (D) Quantification of RT-PCR data show significant changes in the ASII+/ASII − ratio in Smn−/−;SMN2
samples compared with controls. The relative levels of adult and neonatal RYR1 isoforms was significantly altered for both the ASI and ASII
variants in Smn2B/− animals compared with controls. (E,F) The relative levels of adult and neonatal ASII RyR1 transcript variants are not altered in
P14 mice one (E) and seven (F) days post-denervation compared with sham operated mice. N = 3.
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of the Nav1.4 isoform can negatively impact muscle force
production [32].
As expected, we observed a robust increase in Nav1.4
levels in wild type muscle during postnatal development
from P2 to P21 (Figure 5A). Interestingly, in two inde-
pendent mouse models of SMA, there is a decrease in
the levels of Nav1.4 compared with control mice. Speci-
fically, in P5 Smn−/−;SMN2 mice, Nav1.4 and Nav1.5
levels were significantly decreased in hindlimb skeletal
muscle compared with control counterparts (Figure 5B).
Similarly, in muscle from phenotype stage P21 Smn2B/−
mice, there was a decrease in Nav1.4 levels compared
with controls (Figure 5C). In addition to the decrease in
Nav1.4, we observed an increase in Nav1.5 levels in
Smn2B/− muscle (Figure 5C). Sodium channel Nav1.5 isthe predominant isoform expressed in the adult heart
and in early stages of skeletal muscle development [30].
These results suggest that muscle development is de-
layed in SMA model mice and that development is se-
verely impaired, especially in Smn−/−;SMN2 mice, where
both Nav isoform levels are decreased.
To gain a better understanding of how Nav1.4 is mis-
regulated in SMA mice, we assessed the status of proteins
known to regulate sodium channel expression. Hebert and
colleagues [32] have previously demonstrated that the
transcription factor NF1 is recruited to the Nav1.4 gene
promoter by myogenic regulatory factors to enhance its
expression. We did not observe any differences in the
levels of NF1 in muscle from P21 Smn2B/− mice compared
with controls (Figure 5D). Another transcription factor,
ZEB, is a Nav1.4 repressor. As with NF1, we did not
Figure 5 Nav1.4 protein levels are decreased in muscles from
mouse models of SMA. (A) Immunoblot analysis using muscle
lysate from P2, P5, P9, and P21 wild type mice. Nav1.4 protein levels
increase during postnatal muscle development and form the
predominant sodium channel expressed in mature skeletal muscle.
GAPDH served as a loading control (N = 3). (B) Representative
immunoblot with quantification, showing a decrease in levels of
sodium channel Nav1.4 and Nav1.5 in P5 Smn
−/−;SMN2 hindlimb
muscle compared with controls (N = 3). (C) Quantification of
immunoblot analyses in P21 Smn2B/− and control hindlimb muscles
revealed a decrease in Nav1.4 levels. Early in postnatal muscle
development, the Nav1.5 sodium channel isoform is the most
predominant. In P21 Smn2B/− mice, the protein levels of Nav1.5 are
higher than in controls (N = 3). (D) The protein level of the Nav1.4
positive regulator, NF1, is not altered in muscles from P21 Smn2B/−
mice. Similarly, no change was detected in the protein levels of the
Nav1.4 repressor ZEB. (E) Expression of sodium channel Nav1.4 in
control sham and denervated samples 1 and 7 days post-
denervation was assessed by immunoblot (N = 3). A decrease in the
levels of Nav1.4 in muscle was noted at 7 days post-denervation.
*, P < 0.05; **, P < 0.01.
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mice (Figure 5D).
We next investigated whether Nav1.4 expression was
influenced by experimental denervation. There was no
change in Nav1.4 levels one day post-denervation
(Figure 5E). However, a significant decrease was ob-
served seven days following denervation, in agreement
with previous studies [33,34]. Therefore, although the
muscles used in the Nav1.4 expression analysis are not
morphologically denervated, we cannot rule out the
possibility that functional synaptic defects at the NMJ
influence sodium channel expression in muscles from
mouse models of SMA.
SERCA1a protein expression is altered in Smn−/−;SMN2
mice
One possible mechanism that can cause increased un-
stimulated force production is an incomplete removal of
Ca2+ from the sarcoplasm because of decreased levels of
the Ca2+ ATPase pump. The protein responsible for the
Ca2+ uptake following a muscle contraction is the sarco-
plasmic reticulum Ca2+ ATPase (SERCA), of which
SERCA1a is the predominant isoform found in fast-
twitch muscles, such as the TA muscle [35]. The protein
expression of SERCA1a is developmentally regulated. It
peaks by P9 and drops slightly at P21 (Figure 6A). Im-
munoblot analysis revealed a decrease in SERCA1a pro-
tein levels in hindlimb skeletal muscles from P5 Smn−/−;
SMN2 mice compared with control samples (Figure 6B).
Interestingly, levels of calsequestrin, a protein that binds
and stores Ca2+ in the sarcoplasmic reticulum, was un-
changed in Smn−/−;SMN2 muscle compared with con-
trols (Figure 6B), indicating that a Ca2+ handling defect
was likely limited to the sarcoplasmic reticulum pump.
Figure 6 SERCA1a protein level is altered in muscles from Smn−/−;SMN2 mice. (A) Whole muscle lysate was collected from P2, P5, P9, and
P21 wild type mice and immunoblot analysis was performed to assess SERCA1a protein levels. SERCA1a levels increase over time and peak at P9
(N = 3). (B) Immunoblot with quantification showing a decrease in SERCA1a, but not calsequestrin, in hindlimb muscle from P5 Smn−/−;SMN2
mice compared with control (N = 3). (C) Immunoblots were performed on muscle lysates collected from experimentally denervated (DEN) and
sham operated (SHAM) muscle. No change in SERCA1a levels was observed. N = 3, *, P < 0.05.
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SERCA1a protein levels. Protein lysate from gastrocne-
mius muscles was collected from denervated and sham
operated mice. SERCA1a protein levels were unchanged
in skeletal muscle from denervated mice compared with
controls (Figure 6C). This again supports the hypothesis
that the observed decrease in SERCA1a in muscle from
Smn−/−;SMN2 mice could be due to a muscle develop-
mental defect.Discussion
Here, we show that in two mouse models of SMA,
muscle weakness occurs early, being evident prior to any
overt physical denervation and motor neuron loss. This
physiological defect was associated with delayed expres-
sion of mature isoforms of proteins important for muscle
function. Our results therefore point to muscle weakness
coupled with delayed muscle development and provide
new insight into the pathophysiology underlying SMA.
This work highlights the potential of muscle as a thera-
peutic target and warrants further work to identify muscle
directed strategies to increase muscle force production.Muscle weakness in SMA mice
We have employed an ex vivo method in which the
muscle is excised and placed in a chamber where it can
be directly stimulated to contract. By doing so, we re-
duce the negative contribution that degenerating motor
neurons might have in eliciting a contraction, with the
caveat that there may still be functional defects preced-
ing the analysis. We show a decrease in normalized peak
tetanic force in muscle from phenotype stage Smn−/−;
SMN2 mice. Importantly, we show a similar decrease inmuscle force from pre-symptomatic Smn−/−;SMN2 and
Smn2B/− mice prior to any overt motor neuron loss and
denervation, although we cannot rule out the influence
of a functional deficit within the motor neurons. It
should be noted, however, that our physiological results
were normalized to the cross-sectional area of each
muscle tested. Therefore, the overt decrease in muscle
size observed in P5 Smn−/−;SMN2 mice cannot explain
the decrease in force production, per se. In addition, our
experiments performed on pre-symptomatic mice allow
us to rule out the possibility that smaller myofibers are
the reason for the decrease in relative force production,
since no significant difference was observed in muscle
size between pre-symptomatic and control mice. How-
ever, the maturity of the muscle may influence force
production, irrespective of size. As we have observed a
decrease in the mature isoforms of a number of muscle
proteins, we suggest that a decrease in muscle maturity
in P2 Smn−/−;SMN2 and P9 Smn2B/− mice could contrib-
ute to a marked decrease in force production.Delayed expression of mature isoforms of muscle
function proteins in mouse models of SMA
Several groups have indirectly demonstrated impaired
muscle growth in mouse models of SMA by measuring
the cross-sectional area of developing myofibers [18-20].
These analyses suggest that shortly after birth, muscle
development is significantly impaired. During postnatal
muscle development, as myotubes grow to become
myofibers, a switch in expression from neonatal to adult
protein isoforms occurs for many muscle function pro-
teins. A delay in this switch could compromise muscle
maturation and function. Such might be the case with
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perinatal MHC isoforms are predominantly expressed in
muscle from SMA model mice [19,20]. Therefore, we
hypothesized that several other proteins important for
generating muscle contractions could be aberrantly
expressed, with juvenile isoforms predominating rather
than adult ones, which could lead to muscle weakness in
mouse models of SMA. We focused on proteins that are
directly involved in the regulation of muscle contraction,
that is, proteins important for calcium regulation and ac-
tion potential propagation.
RyR1 expression in muscle from mouse models of SMA
Results from our RT-PCR analysis revealed a delay in
the expression of the mature RyR1 splice variants in
skeletal muscle from mouse models of SMA. In pheno-
type stage Smn2B/− mice, we observed a mis-regulation
of both the ASI and ASII alternatively spliced variants.
At P5 in the Smn−/−;SMN2 model, a change in expres-
sion was evident for the ASII variant but not the ASI.
During development, the transition from ASII (−) to
ASII (+) begins at P0 and is complete by P21 [27]. For
the ASI variant, the transition from the neonatal ASI (−)
to the adult ASI (+) form begins only at P8. Therefore,
the timing of the ASI transition probably explains why
we observed the delay in P21 Smn2B/− mice but not in
P5 Smn−/−;SMN2 mice. The functional studies performed
by Kimura et al. demonstrate that neonatal RyR1 is less
active than adult RyR1, as it binds ryanodine with less
affinity than the adult form, and therefore releases less cal-
cium [21]. Thus, the persistent expression of the neonatal
RyR1 variants in mouse models of SMA probably leads to
decreased Ca2+ release from the sarcoplasmic reticulum
to the sarcomere, and subsequently results in weaker
muscle contractions.
Sodium channel expression in muscle from mouse
models of SMA
In skeletal muscle, action potentials are generated and
propagated by voltage-gated sodium channels. Nav1.4 is
the predominant pore-conducting channel in adult
muscle. Its expression significantly increases in mice in
the first two weeks after birth [29,31]. Here we show
that Nav1.4 levels are decreased in muscles from two dif-
ferent mouse models of SMA. This may explain in part
the lower force generation, since there would have been
an insufficient number of available Nav1.4 channels to
generate action potentials during a train. Furthermore,
this period after birth coincides with a period of dra-
matic muscle growth, and Nav1.5 is the major sodium
channel expressed during early muscle development.
Upon denervation of skeletal muscle, the expression of
sodium channels reverts to that which occurs during de-
velopment [31]. The expression of Nav1.5 increases andthat of Nav1.4 decreases in denervated muscle. Indeed,
we observed a decrease in Nav1.4 levels in experimen-
tally denervated muscles (day 7), as well as in muscles
from both SMA mouse models studied. As such, we
cannot rule out the possibility that the mis-regulation of
Nav1.4 is due to denervation in muscle from the symp-
tomatic mice.
The expression of Nav1.4 is positively regulated by the
transcription factor NF1 and is repressed by the tran-
scription factor ZEB [32]. We did not observe any differ-
ences in the expression of these two transcription
factors in Smn2B/− mice. The recruitment of the NF1
protein to the Nav1.4 promoter is mediated through two
transcription factors that are important for muscle dif-
ferentiation, namely myogenin and muscle-specific regu-
latory factor 4 (MRF4). It can be envisaged that a delay
in the expression of myogenic regulatory factors, such as
myogenin and MRF4, or others even more up-stream of
myogenin and MRF4, may explain the deferred Nav1.4
expression in SMA mice.Decreased SERCA1a expression in Smn−/−;SMN2 mice
The results from our fatigue protocol demonstrate an in-
crease in unstimulated force and a decrease in the time
of unstimulated force onset in Smn−/−;SMN2 mice. This
observation may be indicative of a defect in Ca2+ uptake
from the sarcomere to the sarcoplasmic reticulum,
which is supported by the muscle intrinsic decrease in
levels of the SERCA1a Ca2+ pump in muscles of Smn−/−;
SMN2 mice. Defects in Ca2+ handling have previously
been reported in mouse models of muscular dystrophies
[21,36]. Specifically, defects related to Ca2+ uptake and
SERCA1 function have been described in a mouse model
of Duchenne’s muscular dystrophy [37]. Indeed, the
overexpression of SERCA1 in skeletal muscles led to ro-
bust improvements in muscle function and attenuated
muscle pathology in mouse models of muscular dys-
trophy [38]. Furthermore, RyR1 splicing defects resulting
in the expression of the neonatal variants contribute to
the pathogenesis of the neuromuscular disease myotonic
dystrophy type 1 [21]. Thus, the defects we report in
muscles from SMA model mice are reminiscent of those
that occur in other muscle diseases.Conclusions
In summary, we have demonstrated early and profound
muscle weakness, and aberrant expression of muscle pro-
teins in two different mouse models of SMA, which may
contribute to the SMA phenotype. Our results provide
significant insight into muscle defects in SMA pathophysi-
ology and suggest that including skeletal muscle as a
therapeutic target in SMA is warranted.
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